PainChek General Discussion, page-6023

Commercialisations is one of the hardest hurdle a spec stock must overcome. Many stocks with good products and blue sky revenue potential fail at this point.
Do you think RAP will follow PCK's path and that there will be a royal commission into people's coughs that the govt will fund $5mil into?

That's the difference between these 2 stock. One is exciting with big market/revenue potential and the other seems boring at first but now de-risked and basically captured the whole Aus market. So your theory of RAP getting to $1 needs them to be de-risked and getting revenue from a well known entity at the same level as a country's government.

They're both good companies, but both path of commercialisations are not always the same.